This is a Phase II study of a new asthma treatment. The investigators have developed a respirable antisense oligonucleotide, EPI 2010, which targets the adenosine A1 receptor. They have shown that it has anti-bronchoconstrictor and anti-inflammatory actions and can restore normal surfactant secretion, and is effective for 7 days in a rabbit model of asthma. In this proposal, they wish to test this agent in a primate model of asthma. They will do standard toxicology studies of the drug in primates and rodents; quantify the anti-inflammatory activity of the drug in primates; determine if the expression of the adenosine A1 receptor in asthmatic lungs is related to surfactant depletion; and see if EPI 2010 can restore normal surfactant secretion.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44HL057716-02
Application #
2868088
Study Section
Special Emphasis Panel (ZRG1-LBPA (01))
Project Start
1997-09-30
Project End
2000-08-31
Budget Start
1999-09-30
Budget End
2000-08-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Epigenesis Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Cranbury
State
NJ
Country
United States
Zip Code
08512